Alcaftadine - AbbVie
Alternative Names: AGN 229666; Lastacaft; R-89674Latest Information Update: 09 Mar 2022
At a glance
- Originator Vistakon Pharmaceuticals
- Developer AbbVie; Vistakon Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Benzazepines; Eye disorder therapies; Piperidines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Allergic conjunctivitis
Most Recent Events
- 09 Mar 2022 Discontinued - Phase-III for Allergic conjunctivitis (Prevention) in Japan (Ophthalmic)
- 09 Mar 2022 Discontinued - Phase-III for Allergic conjunctivitis in Japan (Ophthalmic)
- 08 May 2020 Allergan has been acquired and merged into AbbVie